(Correction: An earlier version of the article stated that Akademikerpension had assessed that Coloplast could be hurt in the competition to recruit the best employees if it did not report on its tax payments on a country-by-country basis. The pension firm emphasizes that this is only the case over time if the medtech company's competition becomes more transparent, and adds that Coloplast is not suffering any recruitment losses in its current situation. The article also previously stated that Akademikerpension had attempted to push Coloplast into publicizing its national tax payments for over a year. This has been corrected, now reporting that Akademikerpension inquired whether there were any obstacles for doing so).
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers.
Start a free company trial todayMore from MedWatch
More countries back EU Commission investigation into potential Oticon sale
Competition authorities in 13 countries have now asked the EU Commission to examine Demant’s potential sale of Oticon Medical to Cochlear.
FDA ruling to trigger royalty payments for Novo Nordisk
The FDA has just approved a drug licensed by Forma Therapeutics, which Novo Nordisk acquired in September. Royalties from the newly approved cancer treatment will total 13-35% of sales.
USD 1.6bn investment to ensure supplies of sought-after Novo Nordisk drug
After a challenging launch of Wegovy, where Novo Nordisk couldn’t keep up with skyrocketing demand, the pharmaceutical firm is making a large investment to increase production.
Nobel Prize winner: "Good research is driven by curiosity"
The best research comes from curiosity, not personal ambition, says one of the three recipients of Nobel Prize in Chemistry.
Coloplast deputy chair spends USD 7m on shares in firm
Niels Peter Louis-Hansen has bought 56,770 shares in the medtech firm through his company, Aage og Johanne Louis-Hansen.
Associate Director, Global Drug Safety and Pharmacovigilance Scientist 
(Senior) CMC Project Manager 
Quality Assurance Specialist (QAS) in dietary supplements 
Director, QA Commercial Drug Substance, Ascendis Pharma 
Senior or Principal Scientist – Preclinical Biology 
Consultants for FIERS - will you create unique healthcare collaborations? - FIERS - Copenhagen / Denmark 
Chief consultant for Dansk Erhvervs Health and life science 
External Manufacturing Leads 
Laboratory assistants for an exciting QC department 
Head of Regulatory Affairs Danmark 
Systems Verification Manager for Embedded Medical Solutions 
Supply Chain Manager